Gene: A3GALT2
Official Full Name: alpha 1,3-galactosyltransferase 2provided by HGNC
Gene Summary: Predicted to enable N-acetyllactosaminide 3-alpha-galactosyltransferase activity and alpha-1,3-galactosyltransferase activity. Predicted to be involved in lipid glycosylation. Predicted to act upstream of or within glycosphingolipid biosynthetic process. Predicted to be located in Golgi cisterna membrane. Predicted to be active in Golgi apparatus and vesicle. [provided by Alliance of Genome Resources, Apr 2025]
| Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
|---|---|---|---|---|---|---|
| KOA05188 | A3GALT2 Knockout cell line (AC16) | Human | A3GALT2 | 1:3-1:4 | negative | Online Inquiry |
| KOA20634 | A3GALT2 Knockout cell line (BEAS-2B) | Human | A3GALT2 | 1:3~1:4 | negative | Online Inquiry |
| KOA36078 | A3GALT2 Knockout cell line (U-2932) | Human | A3GALT2 | 1:2-1:4 | negative | Online Inquiry |
| KOA51488 | A3GALT2 Knockout cell line (TPC-1) | Human | A3GALT2 | 1:5-1:8 | negative | Online Inquiry |
| KOA66893 | A3GALT2 Knockout cell line (NCM460) | Human | A3GALT2 | 1:2~1:3 | negative | Online Inquiry |
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.